Dutch Startup HeartEye Secures €1.7 Million to Revolutionize Heart Monitoring Outside Hospitals
Netherlands, Sunday, 17 May 2026.
Dutch healthtech company HeartEye raised €1.675 million to accelerate deployment of its portable 12-channel ECG device that delivers hospital-grade cardiac diagnostics in under one minute. The funding will support clinical trials and AI software development as the company approaches CE certification and prepares for market launch.
Healthtech Innovation Addresses Critical Healthcare Gap
This funding represents a significant development in the healthtech sector, specifically targeting mobile cardiac diagnostics technology. HeartEye’s innovation addresses a critical gap in healthcare delivery by making hospital-grade 12-channel electrocardiogram (ECG) recording accessible outside traditional hospital settings [1]. The device enables healthcare professionals to capture comprehensive cardiac data in less than one minute, fundamentally changing how heart conditions are detected and monitored [1]. This technological advancement has the potential to reduce cardiovascular mortality while simultaneously lowering healthcare costs through improved accessibility to advanced heart monitoring capabilities [1].
Investment Led by Regional Development Fund with Notable Tech Entrepreneurs
The €1.675 million funding round was led by ROM InWest, a regional development fund, with participation from several prominent technology entrepreneurs [1]. Notable investors include Pim Berger, co-founder of Schuberg Philis, and Jeroen Tas, co-founder of Mphasis and former Chief Innovation & Strategy Officer at Philips [1][2]. Health Innovations also participated as a returning investor, marking their second investment in HeartEye [1]. The involvement of these seasoned technology executives signals strong confidence in HeartEye’s market potential and technological capabilities. On May 5, 2026, HeartEye announced the formation of an Advisory Board featuring these same investors, demonstrating their commitment to providing strategic guidance beyond capital [2].
How the Technology Works and Its Clinical Applications
HeartEye’s patented mobile 12-channel ECG recorder transforms a traditionally time-consuming and complex diagnostic process into a streamlined procedure that can be performed anywhere [1]. The fully wireless device enables general practitioners, assistants, or nurses to complete a comprehensive 12-channel ECG in under one minute [1]. The system includes a digital platform that allows healthcare providers to share cardiac recordings with physicians or specialists for interpretation and diagnostic support [1]. This capability is particularly valuable for primary care practices and nursing homes, enabling them to perform sophisticated cardiac diagnostics without requiring specialized equipment or extensive training [1]. The technology also has future potential for patient self-monitoring at home, further expanding access to cardiac care [1].
Strategic Capital Deployment and Market Preparation
The funding will support HeartEye through the critical regulatory certification phase required for medical technology products. The company must establish and certify its production processes according to Medical Device Regulation (MDR) requirements, a capital-intensive period during which no clinical revenue can be generated [1]. The investment will specifically fund pivotal clinical studies and continued development of the company’s artificial intelligence software [1]. Additionally, HeartEye will advance its digital healthcare platform and establish production capacity to meet anticipated demand following market authorization [1]. ROM InWest’s involvement reflects the strategic importance of supporting medical technology companies through this challenging regulatory phase, when venture capital firms typically avoid investment due to high technological and market risks [1]. The company is currently approaching CE certification and has begun welcoming pre-orders while preparing for commercial rollout [2].